– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback